Alder BioPharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial and Operating Results
February 26, 2018 16:15 ET
|
Alder BioPharmaceuticals, Inc.
– Strong cash position to support eptinezumab development through approval and commercial launch – – Recently reported pivotal PROMISE 2 top-line data in chronic migraine demonstrates...
Alder BioPharmaceuticals® to Host Conference Call to Discuss Fourth Quarter and Year-End 2017 Financial and Operating Results
February 19, 2018 08:00 ET
|
Alder BioPharmaceuticals, Inc.
BOTHELL, Wash., Feb. 19, 2018 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of...
Alder BioPharmaceuticals, Inc. Announces Exercise in Full of Underwriters’ Option to Purchase Additional 2.50% Convertible Senior Notes Due 2025
February 13, 2018 10:47 ET
|
Alder BioPharmaceuticals, Inc.
BOTHELL, Wash., Feb. 13, 2018 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of...
Alder BioPharmaceuticals® to Present at Two Upcoming February Investor Conferences
February 08, 2018 08:00 ET
|
Alder BioPharmaceuticals, Inc.
BOTHELL, Wash., Feb. 08, 2018 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of...
Alder BioPharmaceuticals, Inc. Announces Closing of $250 Million of 2.50% Convertible Senior Notes Due 2025
February 01, 2018 10:46 ET
|
Alder BioPharmaceuticals, Inc.
BOTHELL, Wash., Feb. 01, 2018 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of...
Alder BioPharmaceuticals, Inc. Announces Pricing of $250 Million of 2.50% Convertible Senior Notes Due 2025
January 29, 2018 22:25 ET
|
Alder BioPharmaceuticals, Inc.
BOTHELL, Wash., Jan. 29, 2018 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of...
Alder BioPharmaceuticals, Inc. Announces Offering of $200 Million of Convertible Senior Notes Due 2025
January 29, 2018 07:10 ET
|
Alder BioPharmaceuticals, Inc.
BOTHELL, Wash., Jan. 29, 2018 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of...
Alder Announces $250 Million Committed Equity Financing
January 08, 2018 08:00 ET
|
Alder BioPharmaceuticals, Inc.
BOTHELL, Wash., Jan. 08, 2018 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of...
Alder BioPharmaceuticals® Enters into European Patent Settlement and Global License Agreement with Teva in the Field of Anti-CGRP-Based Therapy
January 08, 2018 08:00 ET
|
Alder BioPharmaceuticals, Inc.
BOTHELL, Wash., Jan. 08, 2018 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of...
Alder Announces Eptinezumab Significantly Reduces Migraine Risk Meets Primary and All Key Secondary Endpoints in Pivotal PROMISE 2 Phase 3 Trial for Chronic Migraine Prevention
January 08, 2018 07:30 ET
|
Alder BioPharmaceuticals, Inc.
-- Highly statistically significant results with rapid prevention beginning Day One, 50%, 75%, 100% responder rates by month one sustained for three months -- -- 15% of patients had no migraines for...